Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AbbVie Inc. | Emraclidine (CVL-231) - (EMPOWER-1) | Schizophrenia | Phase 2 | Data Released | Oral | Psychiatric |
| AbbVie Inc. | OnabotulinumtoxinA (BOTOX) - (ELATE) | Upper Limb Essential Tremor | Phase 2 | Data Released | Intramuscular | Neurology |
| AbbVie Inc. | ABBV-706 | Solid Tumors, SCLC | Phase 2 | Ongoing | Intravenous | Oncology |
| AbbVie Inc. | CKDB-501A | Moderate-to-severe glabellar lines | Phase 2 | Data Released | Intravenous | N/A |
| AbbVie Inc. | lutikizumab (ABT-981) | Hidradenitis suppurativa (HS) | Phase 2 | Ongoing | Subcutaneous | Immunology: Anti-TNF |
| AbbVie Inc. | AGN-151607- (NOVA) | Post-Operative Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery | Phase 2 | Data Released | intravitreal | Cardiology |
| AbbVie Inc. | RGX-314 - (ALTITUDE) | Diabetic retinopathy | Phase 2 | Data Released | Suprachoroidal injection | Opthalmic |
| AbbVie Inc. | CF Combo (C1/C2/P) | Cystic Fibrosis (CF) | Phase 2 | Trial Discontinued | Oral | Respiratory |
